BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

341 related articles for article (PubMed ID: 20136420)

  • 1. Effect of subconjunctival and intraocular bevacizumab injections on corneal neovascularization in a mouse model.
    Avisar I; Weinberger D; Kremer I
    Curr Eye Res; 2010 Feb; 35(2):108-15. PubMed ID: 20136420
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of experimental corneal neovascularization by using subconjunctival injection of bevacizumab (Avastin).
    Kim TI; Kim SW; Kim S; Kim T; Kim EK
    Cornea; 2008 Apr; 27(3):349-52. PubMed ID: 18362666
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Subconjunctival injection of bevacizumab (avastin) on corneal neovascularization in different rabbit models of corneal angiogenesis.
    Chen WL; Lin CT; Lin NT; Tu IH; Li JW; Chow LP; Liu KR; Hu FR
    Invest Ophthalmol Vis Sci; 2009 Apr; 50(4):1659-65. PubMed ID: 18997093
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of subconjunctival bevacizumab (Avastin) on experimental corneal neovascularization in guinea pigs.
    Hurmeric V; Mumcuoglu T; Erdurman C; Kurt B; Dagli O; Durukan AH
    Cornea; 2008 Apr; 27(3):357-62. PubMed ID: 18362668
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevention and treatment of corneal neovascularization: comparison of different doses of subconjunctival bevacizumab with corticosteroid in experimental rats.
    Hashemian MN; Moghimi S; Kiumehr S; Riazi M; Amoli FA
    Ophthalmic Res; 2009; 42(2):90-5. PubMed ID: 19546599
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of corneal neovascularization by subconjunctival bevacizumab in an animal model.
    Papathanassiou M; Theodossiadis PG; Liarakos VS; Rouvas A; Giamarellos-Bourboulis EJ; Vergados IA
    Am J Ophthalmol; 2008 Mar; 145(3):424-431. PubMed ID: 18207123
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of subconjunctival suramin on corneal neovascularization in rabbits.
    Lee HS; Chung SK
    Cornea; 2010 Jan; 29(1):86-92. PubMed ID: 19907290
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Topical and subconjunctival bevacizumab for corneal neovascularization in an experimental rat model.
    Öner V; Küçükerdönmez C; Akova YA; Çolak A; Karalezli A
    Ophthalmic Res; 2012; 48(3):118-23. PubMed ID: 22538642
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic effect of subconjunctival injection of bevacizumab in the treatment of corneal neovascularization.
    You IC; Kang IS; Lee SH; Yoon KC
    Acta Ophthalmol; 2009 Sep; 87(6):653-8. PubMed ID: 19021596
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of subconjuctival and intraocular bevacizumab injection on angiogenic gene expression levels in a mouse model of corneal neovascularization.
    Dratviman-Storobinsky O; Avraham-Lubin BCR; Hasanreisoglu M; Goldenberg-Cohen N
    Mol Vis; 2009 Nov; 15():2326-38. PubMed ID: 19936307
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevention of corneal neovascularization: comparison of different doses of subconjunctival bevacizumab with its topical form in experimental rats.
    Hashemian MN; Z-Mehrjardi H; Moghimi S; Tahvildari M; Mojazi-Amiri H
    Ophthalmic Res; 2011; 46(1):50-4. PubMed ID: 21212709
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The different effects of early and late bevacizumab (Avastin) injection on inhibiting corneal neovascularization and conjunctivalization in rabbit limbal insufficiency.
    Lin CT; Hu FR; Kuo KT; Chen YM; Chu HS; Lin YH; Chen WL
    Invest Ophthalmol Vis Sci; 2010 Dec; 51(12):6277-85. PubMed ID: 20435600
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Subconjunctival bevacizumab for corneal neovascularization.
    Zaki AA; Farid SF
    Acta Ophthalmol; 2010 Dec; 88(8):868-71. PubMed ID: 19519730
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Subconjunctival bevacizumab for corneal neovascularization.
    Doctor PP; Bhat PV; Foster CS
    Cornea; 2008 Oct; 27(9):992-5. PubMed ID: 18812760
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Subconjunctival bevacizumab injection for corneal neovascularization in recurrent pterygium.
    Bahar I; Kaiserman I; McAllum P; Rootman D; Slomovic A
    Curr Eye Res; 2008 Jan; 33(1):23-8. PubMed ID: 18214740
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of subconjuctival combined treatment of bevacizumab and triamcinolone acetonide on corneal neovascularization in rabbits.
    Kang S; Chung SK
    Cornea; 2010 Feb; 29(2):192-6. PubMed ID: 20098156
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Subconjunctival bevacizumab for corneal neovascularization].
    Gueudry J; Richez F; Tougeron-Brousseau B; Genevois O; Muraine M
    J Fr Ophtalmol; 2010 Nov; 33(9):630-6. PubMed ID: 21035899
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Subconjunctival and intracorneal bevacizumab injection for corneal neovascularization in lipid keratopathy.
    Oh JY; Kim MK; Wee WR
    Cornea; 2009 Oct; 28(9):1070-3. PubMed ID: 19724199
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of subconjunctival bevacizumab on corneal neovascularization: results of a prospective study.
    Benayoun Y; Adenis JP; Casse G; Forte R; Robert PY
    Cornea; 2012 Aug; 31(8):937-44. PubMed ID: 22357391
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of bevacizumab after topical, subconjunctival, and intravitreal administration in rabbits.
    Nomoto H; Shiraga F; Kuno N; Kimura E; Fujii S; Shinomiya K; Nugent AK; Hirooka K; Baba T
    Invest Ophthalmol Vis Sci; 2009 Oct; 50(10):4807-13. PubMed ID: 19324856
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.